| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-08-13 05:23:04 UTC |
|---|
| Update Date | 2022-03-07 02:49:19 UTC |
|---|
| HMDB ID | HMDB0003822 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Cholesteryl acetate |
|---|
| Description | Cholesteryl acetate is a normal human cholesteryl ester present in diverse fluids and organs. Cholesteryl acetate is also present in foods. Food oxidation affects the quality and safety of the human diet by generating compounds with biological activities that can adversely affect health. In particular the susceptibility of cholesterol to oxidation is well known; certain products of cholesterol oxidation have been reported to produce cytotoxic, angiotoxic and carcinogenic effects. Cholesteryl ester (CE) is the major transport and storage form of cholesterol in lipoprotein particles and most cell types. Molecular composition of CE species is of high interest for arteriosclerosis research, i.e., as components of lipoprotein subclasses or in studies investigating the mechanisms involved in the generation of lipid laden foam cells. Thus, it has been shown that CE species in circulating plasma are strongly correlated with development of coronary heart disease. This may be related to specific CE species profiles generated by enzymes involved in lipoprotein metabolism like lecithin:cholesterol acyltransferase (EC 2.3.1.43, LCAT), acyl-coenzyme A:cholesterol acyltransferase 2 (EC 2.3.1.26, ACAT2) or cholesteryl ester transfer protein (CETP). The cholesteryl ester transfer protein has a key role in the metabolism of high-density lipoprotein (HDL), mediating the exchange of lipids between lipoproteins, resulting in the net transfer of cholesteryl ester from HDL to other lipoproteins and in the subsequent uptake of cholesterol by hepatocytes. By increasing the cholesteryl ester content of low-density and very-low-density lipoproteins, CETP promotes the atherogenicity of these lipoproteins. In addition, high plasma concentrations of CETP are associated with reduced concentrations of HDL cholesterol. (PMID: 10918380 , 16458590 , 9420339 , 3343104 , 6721900 , 7278520 ). |
|---|
| Structure | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(C)=O)[C@H](C)CCCC(C)C InChI=1S/C29H48O2/c1-19(2)8-7-9-20(3)25-12-13-26-24-11-10-22-18-23(31-21(4)30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-20,23-27H,7-9,11-18H2,1-6H3/t20-,23+,24+,25-,26+,27+,28+,29-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-Cholesteryl acetate | ChEBI | | (3beta)-Cholest-5-en-3-ol acetate | ChEBI | | 3-Cholesteryl acetate | ChEBI | | 3beta-Acetoxycholest-5-ene | ChEBI | | 5-Cholesten-3beta-ol acetate | ChEBI | | Cholest-5-en-3beta-ol acetate | ChEBI | | Cholest-5-en-3beta-yl acetate | ChEBI | | Cholesterol 3-acetate | ChEBI | | Cholesterol 3beta-acetate | ChEBI | | Cholesterol acetate | ChEBI | | (-)-Cholesteryl acetic acid | Generator | | (3b)-Cholest-5-en-3-ol acetate | Generator | | (3b)-Cholest-5-en-3-ol acetic acid | Generator | | (3beta)-Cholest-5-en-3-ol acetic acid | Generator | | (3Β)-cholest-5-en-3-ol acetate | Generator | | (3Β)-cholest-5-en-3-ol acetic acid | Generator | | 3-Cholesteryl acetic acid | Generator | | 3b-Acetoxycholest-5-ene | Generator | | 3Β-acetoxycholest-5-ene | Generator | | 5-Cholesten-3b-ol acetate | Generator | | 5-Cholesten-3b-ol acetic acid | Generator | | 5-Cholesten-3beta-ol acetic acid | Generator | | 5-Cholesten-3β-ol acetate | Generator | | 5-Cholesten-3β-ol acetic acid | Generator | | Cholest-5-en-3b-ol acetate | Generator | | Cholest-5-en-3b-ol acetic acid | Generator | | Cholest-5-en-3beta-ol acetic acid | Generator | | Cholest-5-en-3β-ol acetate | Generator | | Cholest-5-en-3β-ol acetic acid | Generator | | Cholest-5-en-3b-yl acetate | Generator | | Cholest-5-en-3b-yl acetic acid | Generator | | Cholest-5-en-3beta-yl acetic acid | Generator | | Cholest-5-en-3β-yl acetate | Generator | | Cholest-5-en-3β-yl acetic acid | Generator | | Cholesterol 3-acetic acid | Generator | | Cholesterol 3b-acetate | Generator | | Cholesterol 3b-acetic acid | Generator | | Cholesterol 3beta-acetic acid | Generator | | Cholesterol 3β-acetate | Generator | | Cholesterol 3β-acetic acid | Generator | | Cholesterol acetic acid | Generator | | Cholesteryl acetic acid | Generator | | Cholesterin acetate | HMDB | | Cholesteryl acetate | HMDB |
|
|---|
| Chemical Formula | C29H48O2 |
|---|
| Average Molecular Weight | 428.701 |
|---|
| Monoisotopic Molecular Weight | 428.365430786 |
|---|
| IUPAC Name | (1S,2R,5S,10S,11S,14R,15R)-2,15-dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-5-yl acetate |
|---|
| Traditional Name | (1S,2R,5S,10S,11S,14R,15R)-2,15-dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-5-yl acetate |
|---|
| CAS Registry Number | 604-35-3 |
|---|
| SMILES | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(C)=O)[C@H](C)CCCC(C)C |
|---|
| InChI Identifier | InChI=1S/C29H48O2/c1-19(2)8-7-9-20(3)25-12-13-26-24-11-10-22-18-23(31-21(4)30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-20,23-27H,7-9,11-18H2,1-6H3/t20-,23+,24+,25-,26+,27+,28+,29-/m1/s1 |
|---|
| InChI Key | XUGISPSHIFXEHZ-VEVYEIKRSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as cholesteryl esters. Cholesteryl esters are compounds containing an esterified cholestane moiety. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Steroid esters |
|---|
| Direct Parent | Cholesteryl esters |
|---|
| Alternative Parents | |
|---|
| Substituents | - Cholesteryl ester
- Cholesterol
- Cholestane-skeleton
- Delta-5-steroid
- Carboxylic acid ester
- Monocarboxylic acid or derivatives
- Carboxylic acid derivative
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | |
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 9.75 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 31.0408 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.74 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 4053.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 966.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 371.3 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 444.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 803.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 1423.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 1295.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 108.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 2592.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 821.7 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2594.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 922.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 707.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 496.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 838.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 9.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| General References | - Liebisch G, Binder M, Schifferer R, Langmann T, Schulz B, Schmitz G: High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim Biophys Acta. 2006 Jan;1761(1):121-8. Epub 2006 Jan 18. [PubMed:16458590 ]
- Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998 Jan 8;338(2):86-93. [PubMed:9420339 ]
- Pelillo M, Galletti G, Lercker G: Mass spectral fragmentations of cholesterol acetate oxidation products. Rapid Commun Mass Spectrom. 2000;14(14):1275-9. [PubMed:10918380 ]
- Nicolaides N, Flores A, Santos EC, Robin JB, Smith RE: The lipids of chalazia. Invest Ophthalmol Vis Sci. 1988 Mar;29(3):482-6. [PubMed:3343104 ]
- Dolphin PJ, Breckenridge WC, Dolphin MA, Tan MH: The lipoproteins of human umbilical cord blood apolipoprotein and lipid levels. Atherosclerosis. 1984 Apr;51(1):109-22. [PubMed:6721900 ]
- Perkins EG, Hendren DJ, Bauer JE, El-Hamdy AH: High performance reversed phase chromatography of cholesterol and cholesteryl esters of human plasma lipoproteins. Lipids. 1981 Aug;16(8):609-13. [PubMed:7278520 ]
|
|---|